AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03197922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerin Suppository
Description: If no continent bowel movement occurs with the first sit, trained staff administer a dose of a liquid glycerin suppository, immediately followed by another sit to ensure any resulting bowel movement is continent. Glycerin suppositories are replaced by bisacodyl if 2 days pass without a continent bowel movement using the liquid glycerin suppository. Behavioral intervention consists of potent positive reinforcers when a continent bowel movement occurs. As independent continent bowel movements begin to occur, the need for the medical regimen diminishes, and is gradually faded out entirely.
Study NCT03197922 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
Study NCT03261791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib mesylate tablets 500 mg po qd.
Study NCT00874848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG Injection
Description: 4 mg/kg i.v. over 2 hrs, weekly, in three week cycles
Study NCT00874848 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: initial loading dose of 400 mg/m\^2 over 120 min and subsequent doses at 250 mg/m\^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
Study NCT00874848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: initial loading dose of 400 mg/m\^2 over 120 min and subsequent doses at 250 mg/m\^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
Study NCT00874848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 200 mg/m\^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
Study NCT01358318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satiety
Description: Single consumption of snack bars to determine satiety and food intake at next meal.
Study NCT01268384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Capecitabine
Description: Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
Study NCT00874848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m\^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
Study NCT00874848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
Study NCT00874848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
Study NCT01907763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTB07 200mg
Study NCT01907763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTB07 400mg
Study NCT01907763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOTB 200mg placebo
Description: Placebo of SOTB07 200mg
Study NCT01907763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTB 200mg placebo
Description: Placebo of SOTB07 200mg
Study NCT01907763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOTB 400mg placebo
Description: Placebo of SOTB07 400mg
Study NCT01907763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTB 400mg placebo
Description: Placebo of SOTB07 400mg
Study NCT00882960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous fentanyl
Description: An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
Study NCT00882960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-nasal fentanyl
Description: a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
Study NCT03015753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: The 12-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 32-short form Yang-style Tai Chi Chuan will be adopted. The instructor-led sessions will be operated by qualified Tai Chi masters. The training activity will be delivered in group. The group size is 15 to 18 persons.
Study NCT03015753 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list control group
Description: At the end of the trial, participants in this arm will be offered Tai Chi training similar as Tai Chi training (TC) group.
Study NCT04125342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preventive Conditioned NIV Therapy after planned extubation
Description: Conditioned NIV during 48 hours following extubation.
Study NCT04125342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Preventive HFOT after planned extubation
Description: HFOT set according to patients tolerance during 48 hours following extubation
Study NCT02042924 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FLT PET/CT
Description: Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
Study NCT02042924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
Study NCT01469286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEA
Description: Electroacupuncture at ST36
Study NCT01469286 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-TEA
Description: Electroacupuncture at sham-points
Study NCT02544529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echothiophate Iodide 0.03% Ophthalmic Solution
Description: one drop to each eye three times per week for 18 weeks
Study NCT02544529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboxymethylcellulose Sodium (0.5%)
Description: one drop to each eye three times per week for 18 weeks
Study NCT01458899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Oral tablets, single 4mg dose
Study NCT03073096 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: LVA at time of nodal dissection
Description: Patients will receive a lymphatic-venous anastomosis at time of their required nodal dissection
Study NCT04347265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP
Description: Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, with 3 Hz frequency and a 250µs pulse width, at the maximal tolerable intensity, to cause an tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
Study NCT00612196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
Study NCT00159588 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Betablockers or other preventive drugs based on primary headache type
Description: Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
Study NCT00612196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00892710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5 IV every 21 days
Study NCT02034838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir 300mg boosted with ritonavir 50 mg
Description: atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.~atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)
Study NCT03348176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable exposure
Description: Repeated exposure to variety of vegetables
Study NCT03348176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIPP-Feeding Infants
Description: Promoting responsive feeding practices
Study NCT03348176 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Phone calls with mother about development of child, no advice on complementary feeding
Study NCT02451124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-endoscopic inflatable balloon for the esophagus
Description: Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
Study NCT02451124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03193996 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 4DCT
Description: 4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
Study NCT02929017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SUPPORT
Description: Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
Study NCT02929017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Currently Available Printed Material
Description: Subjects will receive their usual standard of care, including currently available printed patient material.
Study NCT02451124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02451124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagogastroduodenoscopy
Description: Standard of care, patients digestive tract scoped post balloon brushing
Study NCT01247194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI-461
Description: capsule, oral, once daily for 3 days
Study NCT01247194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: capsules, oral, once daily for 3 days
Study NCT00897221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone oral solution 100mg/mL
Description: Deferiprone oral solution (20 mg/kg/day)
Study NCT00897221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone oral solution 100 mg/mL
Description: Deferiprone oral solution(40mg/kg/day)
Study NCT00612521 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adenosine
Description: For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
Study NCT00209040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic Startle Testing
Description: See protocol description for methodological details
Study NCT02218034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190168 Formulation 1
Description: AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Study NCT02218034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190168 Formulation 2
Description: AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Study NCT02218034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tazarotene gel 0.1%
Description: Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Study NCT06311422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin nanoceramic block
Description: Resin-based CAD/CAM materials
Study NCT06311422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zirconia-reinforced lithium silicate
Description: zirconia reinforced lithium silicate ceramic
Study NCT04231604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Lust for Life
Description: A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in adolescents. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the adolescents' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
Study NCT04231604 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list control
Description: Control group placed on a twelve-week waiting list.
Study NCT02057159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroVax
Description: TCR peptides in IFA
Study NCT02057159 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IFA Placebo
Description: IFA Placebo
Study NCT02150915 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture therapy (leopard spot needling technique)
Description: Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
Study NCT02150915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (leopard spot needling technique)
Description: Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
Study NCT02017925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Undergo pulmonary rehabilitation
Study NCT02017925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary complications management/prevention
Description: Undergo pulmonary rehabilitation
Study NCT02017925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02017925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT06330259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: menstrual cycle monitoring
Description: frequent serum sampling and 3D ultrasound
Study NCT01772732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simotinib Hydrochloride
Study NCT00595478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)/CBT+CM
Description: Behavioral Treatment
Study NCT00595478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)/CBT
Description: Behavioral Treatment
Study NCT03401671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.
Study NCT01635855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero®
Description: Hyaluronic acid dermal filler
Study NCT02218034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tazarotene cream 0.1%
Description: Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Study NCT03764241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 15mg/QD will be applied for 3 months unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
Study NCT00293995 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Repair of unilateral inguinal hernia
Study NCT02487004 — intervention group
Intervention type: DEVICE
Intervention: hemodialysis
Study NCT00550693 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine-impregnated foam dressing
Description: Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
Study NCT04030793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized transcranial direct current stimulation
Description: Based on tDCS stimulation, individualized stimulation during 30 minutes with sitting position.
Study NCT00159588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betablockers or other preventive drugs based on primary headache type
Description: Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
Study NCT02633956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid
Description: Once a day (QD) by mouth (PO)
Study NCT02633956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.
Study NCT02633956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated.
Study NCT02633956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day (QD) by mouth (PO)
Study NCT02567461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
Study NCT02567461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
Study NCT02567461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
Study NCT02567461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
Study NCT02567461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
Study NCT04030793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional transcranial direct current stimulation
Description: Conventional tDCS stimulation during 30 minutes with sitting position.
Study NCT03764241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K Antagonist
Description: warfarin (INR 2.0-2.5) will be applied for 3 months unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.